Driving Stage Shift in Oncology with AI: Qure.ai at 2026 ASCO® Annual Meeting
At the ASCO 2026 Annual Meeting, Qure.ai is spotlighting how AI can enable a meaningful stage shift in oncology by moving care from reactive to proactive. By turning clinical data into actionable insights, Qure.ai helps identify patients earlier, accelerate intervention, and support more timely access to treatment, addressing one of the most critical gaps in cancer care today.
A key focus is the role of AI powered imaging biomarkers in bridging the gap between clinical trials and real-world impact. Qure.ai demonstrates how these biomarkers & guideline concorded workflows can be operationalized at scale to support patient identification, improve stratification, and enhance decision-making across care teams. This ability to integrate seamlessly into clinical workflows ensures that opportunities for early action are not missed.
With 26 FDA-cleared indications and deployments across millions of patients globally, Qure.ai continues to deliver clinically validated, scalable AI solutions. Visit Booth #IH12 at ASCO 2026 to explore how AI-driven patient identification and coordinated care can enable early diagnosis, reduce delays, and ultimately improve patient outcomes.
To know more, visit: https://www.qure.ai/events/asco-2026
At the ASCO 2026 Annual Meeting, Qure.ai is spotlighting how AI can enable a meaningful stage shift in oncology by moving care from reactive to proactive. By turning clinical data into actionable insights, Qure.ai helps identify patients earlier, accelerate intervention, and support more timely access to treatment, addressing one of the most critical gaps in cancer care today.
A key focus is the role of AI powered imaging biomarkers in bridging the gap between clinical trials and real-world impact. Qure.ai demonstrates how these biomarkers & guideline concorded workflows can be operationalized at scale to support patient identification, improve stratification, and enhance decision-making across care teams. This ability to integrate seamlessly into clinical workflows ensures that opportunities for early action are not missed.
With 26 FDA-cleared indications and deployments across millions of patients globally, Qure.ai continues to deliver clinically validated, scalable AI solutions. Visit Booth #IH12 at ASCO 2026 to explore how AI-driven patient identification and coordinated care can enable early diagnosis, reduce delays, and ultimately improve patient outcomes.
To know more, visit: https://www.qure.ai/events/asco-2026